Ocugen (OCGN) News Today $0.92 +0.04 (+4.55%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt DiseaseNovember 20 at 7:30 AM | globenewswire.comOcugen (NASDAQ:OCGN) Receives "Buy" Rating from Chardan CapitalNovember 20 at 2:40 AM | americanbankingnews.comOcugen reports positive data for OCU400, OCU410November 19 at 9:50 PM | msn.comOcugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trialNovember 19 at 9:50 PM | markets.businessinsider.comOcugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationNovember 19 at 7:02 AM | globenewswire.comOcugen Appoints Ramesh Ramachandran as Financial OfficerNovember 16, 2024 | markets.businessinsider.comWall Street Expects These 2 Under-the-Radar Growth Stocks to OutperformNovember 16, 2024 | msn.comOcugen’s Promising Pipeline and Strategic Advances Support Buy RatingNovember 16, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for Ocugen FY2024 Earnings?November 16, 2024 | americanbankingnews.comOcugen’s Gene Therapies Show Promising Results: Analyst Recommends BuyNovember 14, 2024 | markets.businessinsider.comHC Wainwright Has Negative Outlook of Ocugen FY2024 EarningsOcugen, Inc. (NASDAQ:OCGN - Free Report) - Equities researchers at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for Ocugen in a note issued to investors on Monday, November 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.18) per shaNovember 14, 2024 | marketbeat.comOcugen’s Promising Gene Therapy Advancements and Financial Stability Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comOcugen to Present Innovations at Nasdaq Clinical ShowcaseNovember 13, 2024 | markets.businessinsider.comOcugen’s Strong Financial Management and Promising Gene Therapy Pipeline Drive Buy RatingNovember 11, 2024 | markets.businessinsider.comOcugen (NASDAQ:OCGN) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Ocugen in a research note on Monday.November 11, 2024 | marketbeat.comChardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN)Chardan Capital reissued a "buy" rating and set a $6.00 price objective on shares of Ocugen in a research report on Friday.November 11, 2024 | marketbeat.comOcugen, Inc. (NASDAQ:OCGN) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comOcugen: Progress in Gene Therapy and Financial OutlookNovember 9, 2024 | markets.businessinsider.comOcugen secures $30M debt fundingNovember 8, 2024 | msn.comOcugen Provides Business Update with Third Quarter 2024 Financial ResultsNovember 8, 2024 | globenewswire.comOcugen Secures $30 Million in Debt FundingNovember 7, 2024 | globenewswire.comThose who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%November 1, 2024 | finance.yahoo.comOcugen (OCGN) Set to Announce Quarterly Earnings on FridayOcugen (NASDAQ:OCGN) will be releasing earnings before the market opens on Friday, November 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=636742)November 1, 2024 | marketbeat.comPromising Developments in Ocugen’s Pipeline Support Buy RatingOctober 31, 2024 | markets.businessinsider.comOcugen to Spotlight Gene Therapy Advances at Upcoming Clinical ShowcaseOctober 31, 2024 | msn.comOcugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024October 28, 2024 | globenewswire.comOcugen Advances Stargardt Disease Trial with Promising Gene TherapyOctober 24, 2024 | msn.comOcugen’s Promising Pipeline and Valuation Propel Buy RatingOctober 24, 2024 | markets.businessinsider.comOcugen's (OCGN) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Ocugen in a research report on Wednesday.October 23, 2024 | marketbeat.comOcugen announces DSMB for OCU410ST trial approved enrollment for second phaseOctober 23, 2024 | markets.businessinsider.comData and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt DiseaseOctober 22, 2024 | globenewswire.comOcugen Announces Third Quarter Financial Results Conference CallOctober 18, 2024 | msn.comOcugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial ResultsOctober 17, 2024 | globenewswire.comState Street Corp's Strategic Acquisition of Shares in Ocugen IncOctober 16, 2024 | finance.yahoo.comOcugen (NASDAQ:OCGN) Receives New Coverage from Analysts at Maxim GroupMaxim Group initiated coverage on Ocugen in a research note on Tuesday. They issued a "buy" rating and a $4.00 price target on the stock.October 15, 2024 | marketbeat.comOcugen Advances Promising Pipeline Amid Financial RestraintsOctober 14, 2024 | msn.comOcugen’s CEO to Present at 2024 Maxim Healthcare Virtual SummitOctober 11, 2024 | msn.comOcugen to Participate in 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | finance.yahoo.comFDA Greenlights Ocugen’s Revolutionary Eye Treatment: What It Means for Vision CareOctober 10, 2024 | msn.comOcugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesOctober 9, 2024 | finance.yahoo.comOcugen: FDA Lifts Clinical Hold On Investigational New Drug Application For Phase 1 Trial Of OCU200October 9, 2024 | markets.businessinsider.comOcugen says FDA has removed clinical hold on eye drug OCU200October 9, 2024 | msn.comOcugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical TrialOctober 9, 2024 | globenewswire.comOcugen (NASDAQ:OCGN) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comAttention Ocugen, Inc. (OCGN) Shareholders: Grabar Law Office Investigates Claims on Your BehalfOctober 5, 2024 | markets.businessinsider.comOcugen, Inc. Set to Present at 2024 Cell & Gene Meeting on the MesaOctober 3, 2024 | msn.comOcugen to Present at the 2024 Cell & Gene Meeting on the MesaOctober 2, 2024 | globenewswire.comOcugen, Inc. (OCGN) Shareholder Notice: Grabar Law Office Investigates Claims on Your BehalfSeptember 26, 2024 | markets.businessinsider.comOcugen, Inc. (OCGN) interactive stock chart – Yahoo FinanceSeptember 25, 2024 | au.finance.yahoo.comOcugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines ConferenceSeptember 24, 2024 | globenewswire.com Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. OCGN Media Mentions By Week OCGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCGN News Sentiment▼0.340.45▲Average Medical News Sentiment OCGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCGN Articles This Week▼155▲OCGN Articles Average Week Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies aTyr Pharma News LENZ Therapeutics News Immatics News Vir Biotechnology News Relay Therapeutics News Replimune Group News Autolus Therapeutics News Cullinan Therapeutics News CARGO Therapeutics News Anavex Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
